Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(+)-2-(4-biphenyl)propionic acid is a small molecule compound belonging to the class of biphenyl propionic acids. It is an experimental drug that acts as an inhibitor of prostaglandin G/H synthase 1 (also known as cyclooxygenase 1 or COX1), which is involved in the biosynthesis of prostaglandins from arachidonic acid. Prostaglandin G/H synthase 1 inhibition reduces the formation of pro-inflammatory mediators, suggesting potential anti-inflammatory activity. The compound has not been approved for clinical use and there are no reported indications or completed clinical trials[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (+)-2-(4-biphenyl)propionic acid.